Aytu BioPharma, Inc. (AYTU) Analyst/Investor Day Transcript

Core Insights - Aytu Biopharma has officially launched Exxua, a first-in-class treatment for major depressive disorder, marking a significant milestone in the company's history [1] - The sales force for Exxua is fully deployed and actively generating prescriptions, indicating strong market enthusiasm and potential for growth [2] Company Developments - The launch of Exxua represents a transformational opportunity for Aytu Biopharma as it introduces the first and only 5-HT1a agonist in the market [1] - The company is currently experiencing positive feedback from the field regarding the new product, suggesting a promising reception among healthcare providers [2]